Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial

Allyson J. Ocean, Kenneth L. Pennington, Michael J. Guarino, Arif Sheikh, Tanios Bekaii-Saab, Aldo N. Serafini, Daniel Lee, Max W. Sung, Seza A. Gulec, Stanley J. Goldsmith, Timothy Manzone, Michael Holt, Bert H. O'Neil, Nathan Hall, Alberto J. Montero, John Kauh, David V. Gold, Heather Horne, William A. Wegener, David M. Goldenberg

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Fingerprint Dive into the research topics of 'Fractionated radioimmunotherapy with <sup>90</sup>Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences